Dr.Datsons Labs (Delisted) share news and announcements

BSE: 533412

Formerly Aanjaneya Lifecare

Last traded ₹6.40 on 21 May 2015

Delisted on 14 Feb 2020.

Dr.Datsons Labs share news and announcements

899 announcements, routine notices left out, newest first. Page 5 of 18.

May 2014
- 22 May · Disclosure
  Stream Value Fund has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 (opens in a new tab)
- 21 May · Updates
  Dr. Datson's Labs Limited has informed the Exchange that in accordance with the provisions of Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992, the trading window of the Company will remain closed from May 19, 2014 to May 31, 2014 for the purpose of consider and approve the Audited Financial Results for the financial year ended March 31, 2014. (opens in a new tab)
- 20 May · Disclosure
  Vide letter dated May 02, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992. (opens in a new tab)
- 20 May · Disclosure
  Vide letter dated April 29, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992. (opens in a new tab)
- 19 May · Board meeting
  To approve the Audited Financial Results for the financial year ended March 31, 2014. Any other matter with the permission of the Chair. (opens in a new tab)
- 19 May · Business
  Dr.Datsons Labs Ltd has informed BSE that Mires B.V ("Proposed Acquirer") completed the valuation of the two plants of the Company situated at Mahad and Pune. The Total Fair Valuation of ....
- 19 May · Updates
  Dr. Datson's Labs Limited has informed the Exchange that Mires B.V ( Proposed Acquirer ) completed the valuation of the two plants of the company situated at Mahad and Pune. The Total Fair Valuation of the Company as stood at Rs 350 Crores out which valuation of the fixed assets of the company stood at Rs. 270 Crores. The Detailed term sheet for process of proposed Acquisition will be received by the company shortly.The Company undertakes to take all necessary steps for the Benefit of the stakeholders of the company. (opens in a new tab)
- 15 May · Board meeting
  Dr.Datsons Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 15, 2014, inter alia, has approved the following: Issuance of 1,10,55,720 .... (opens in a new tab)
- 15 May · Board meeting
  Dr. Datson's Labs Limited has informed the Exchange regarding a outcome of Board Meeting held on May 15, 2014. (opens in a new tab)
- 15 May · Meeting
  Dr. Datson's Labs Limited has submitted to the Exchange a copy of the postal ballot notice of the Company. (opens in a new tab)
- 15 May · Meeting
  Dr.Datsons Labs Ltd has informed BSE that the members of the Company will consider to approve the resolutions by way of Postal Ballot. (opens in a new tab)
- 14 May · Meeting
  Dr. Datson's Labs Limited has submitted to the Exchange a copy of the Calendar of Events for the Postal Ballot process of the Company. (opens in a new tab)
- 13 May · Meeting
  Dr.Datsons Labs Ltd has submitted to BSE a copy of Calendar of Events for Postal Ballot. (opens in a new tab)
- 12 May · Disclosure
  Vide letter dated May 08, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992. (opens in a new tab)
- 12 May · Board meeting
  Dr. Datson's Labs Limited has submitted to the Exchange the outcome of Meeting of the Board of Directors of the Company held on May 10, 2014. (opens in a new tab)
- 10 May · Board meeting
  Dr.Datsons Labs Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 10, 2014, has : 1. Approved and finalized the Notice of Postal Ballot .... (opens in a new tab)
- 9 May · Disclosure
  Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated May 09, 2014 a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992. (opens in a new tab)
- 9 May · Disclosure
  Dr.Datsons Labs Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 (opens in a new tab)
- 9 May · Board meeting
  (1) To consider issue and allotment of equity shares Pursuant to FCCBs conversion notice (s) received from the Bondholders of the Company.(2) Any other matter with the permission of the Chair.
- 8 May · Disclosure
  Leman Diversified Fund has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 (opens in a new tab)
- 8 May · Board Meeting on May 15, 2014
  Dr.Datsons Labs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 15, 2014, inter alia, to consider issue and allotment of equity shares Pursuant ....
- 8 May · Disclosure
  Davos International Fund has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 (opens in a new tab)
- 8 May · Disclosure
  Vide letter dated May 07, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 along with disclosure under regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992. (opens in a new tab)
- 7 May · Disclosure
  Davos International Fund has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 (opens in a new tab)
- 2 May · Disclosure
  Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated May 02, 2014 a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992. (opens in a new tab)
- 2 May · Disclosure
  Dr.Datsons Labs Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 (opens in a new tab)
- 2 May · Disclosure
  Leman Diversified Fund has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 (opens in a new tab)
Apr 2014
- 30 Apr · Disclosure
  Sparrow Asia Diversified Opprotunities Fund has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 (opens in a new tab)
- 29 Apr · Board Meeting on May 10, 2014
  Dr.Datsons Labs Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on May 10, 2014, to transact the following: 1. . Increase in authorize capital ....
- 29 Apr · Board meeting
  1. To consider Increase in authorize capital of the company from Rs 500,000,000 to Rs. 800,000,000 subject to the approval of the Members of the Company. 2. To consider the Company's fund raising program by way of issue of Equity shares on preferential basis to Non Promoters up to US$ 25.00 million, as per the Applicable provisions of the companies Act 2013 and SEBI Regulations, subject to the approval of the Members of the Company. 3. To consider issue of Foreign Currency convertible Bonds [FCCBs], American Depository Receipts [ADR] and Global Depository Receipts [GDR] up to US$ 25.00 million as per the Applicable provisions of the companies Act 2013 and SEBI Regulations, subject to the approval of the Members of the Company. 4. To consider the amendment in Other Object Clauses in the Memorandum of Association of the Company, subject to the approval of the Members of the Company. 5. To consider conducting Postal Ballot of the Company for the above matters pursuant to Section 110 of the Companies Act, 2013 and Companies (Management and Administration) Rules ,2014 and to finalize the Notice of Postal Ballot for the same. 6. To consider appointment of Scrutinizer to oversee the Postal Ballot process of the Company. (opens in a new tab)
- 28 Apr · Updates
  Dr. Datson's Labs Limited has informed the Exchange that "the company has received Letter of interest between Mires B.V a European based Pharma Company ( Proposed Acquirer ) and Dr. Datsons Labs Limited ( Target Company ) Summarize their mutual interest in the Acquirer buying the Target Company. The Acquirer Proposed the Enterprise Valuation of the target company is decided post Due Diligence. The Acquirer proposed to buy Majority stake in the target company and The Company undertakes to take all necessary steps for the Benefit of the stakeholders of the company". (opens in a new tab)
- 28 Apr · Business
  Dr.Datsons Labs Ltd has informed BSE that the Company has received Letter of interest between Mires B.V a European based Pharma Company ("Proposed Acquirer") and Dr. Datsons Labs Limited ....
- 21 Apr · Disclosure
  Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated April 18, 2014 a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992. (opens in a new tab)
- 21 Apr · Disclosure
  Vide letter dated April 18, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 along with disclosure under regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992. (opens in a new tab)
- 19 Apr · Disclosure
  Dr.Datsons Labs Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 (opens in a new tab)
- 18 Apr · Disclosure
  Stream Value Fund has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 (opens in a new tab)
- 16 Apr · Disclosure
  Dr.Datsons Labs Ltd has submitted the disclosures under Reg.13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992 (opens in a new tab)
- 16 Apr · Disclosure
  Vide letter dated April 15, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992. (opens in a new tab)
- 16 Apr · Disclosure
  Leman Diversified Fund has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 (opens in a new tab)
- 16 Apr · Clarifies on News item
  With reference to the news item appearing in the leading financial daily titled "Videocon set to acquire Datsons Labs for Rs. 350 cr", Dr.Datsons Labs Ltd has Clarified to BSE as under: ....
- 16 Apr · News Verification
  News Verification : The media had reports that Dr. Datson's Labs Limited "Videocon set to acquire Datsons Labs for Rs. 350 crores". The Exchange, in order to verify the accuracy or otherwise of the information reported in the media and to inform the market place so that the interest of the investors is safeguarded, had written to the company. Dr. Datson's Labs Limited has vide its letter inter-alia stated,"We are not aware of the source for the information appearing in Business standard & deny the news item. We once again reiterate that news article is based on speculation and company has not released any press release or notification regarding the same. The company is in process of negotiating with various pharma companies & strategic investors for Stake sale in company to fuel our expansion plans for the benefit of shareholders and it is the policy of the company to inform the stock exchanges whenever such a proposal crystallize. We would further like to inform that such decisions are intimated to your esteemed exchange by the way of outcomes of board meetings of the company."
- 16 Apr · Disclosure
  Vide letter dated April 15, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992. (opens in a new tab)
- 16 Apr · Disclosure
  Vide letter dated April 15, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of Disclosure under Regulation 13(1) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992. (opens in a new tab)
- 16 Apr · Disclosure
  Sparrow Asia Diversified Opportunities Fund has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 (opens in a new tab)
- 16 Apr · Disclosure
  Davos International Fund has submitted the disclosures under Reg. 29(1) of SEBI (SAST) Regulations, 2011 (opens in a new tab)
- 15 Apr · Disclosure
  Vide letter dated April 11 , 2014 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. (opens in a new tab)
- 14 Apr · Shareholding Pattern for March 31, 2014
  Dr.Datsons Labs Ltd has informed BSE about the Shareholding Pattern for the Quarter ended March 31, 2014. (opens in a new tab)
- 11 Apr · Disclosure
  Finaventure Capital Ltd has submitted the disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 to BSE (opens in a new tab)
- 11 Apr · Disclosure
  Religare Finvest Ltd has submitted the disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 (opens in a new tab)
- 7 Apr · Management
  Dr. Datson's Labs Limited has informed the Exchange that Mr. Chandulal Champaklal Shah, Chairman Emeritus of the Company, has tendered his resignation from the Chairman Emeritus of the Company with effect from April 05, 2014. (opens in a new tab)